HeartLight Endoscopic Ablation System now available in the Netherlands


CardioFocus has announced that its technology is now available in the Netherlands. Physicians at Isala Klinieken in Zwolle were the first in the country to incorporate visually guided ablation into their regular therapeutic practice and have successfully treated several patients.

Arif Elvan, who led the first cases, said, “The HeartLight EAS technology presents a unique approach to atrial fibrillation ablation, offering direct, real-time visualisation inside a beating heart , as well as remarkable ease of use for physician operators. Our clinical experience to date is in line with research showing the high acute efficacy of the system, and we are excited to bring this innovative treatment option to patients in the Netherlands.”

The HeartLight EAS is a unique catheter ablation technology that incorporates an endoscope for direct visualisation and a compliant, dynamically adjustable balloon catheter designed for improved contact with the pulmonary vein ostium irrespective of the individual patient anatomy. It also utilises laser energy for more efficient, durable and precise ablation treatment. Research presented by V Y Reddy at Heart Rhythm 2011 demonstrated an acute pulmonary vein isolation rate of 99%, with approximately 77% of patients achieving durable freedom from atrial fibrillation after a single procedure.

“Isala Klinieken is one of the premier cardiology centers in the country and we are pleased they have chosen to incorporate the HeartLight EAS technology into their AF treatment offering,” said Stephen Sagon, President and CEO of CardioFocus. “Within the last year, our technology has entered into several new countries and become established at numerous European sites. We look forward to building on this momentum and continuing adoption of HeartLight EAS throughout Europe. “

HeartLight EAS is currently available in the Czech Republic, Germany, Italy, the UK and now the Netherlands. The device is investigational in the USA, and currently the focus of a pivotal trial initiated in 2012.